L. Silva Miguel

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal

L. Silva Miguel, Francisca Vargas Lopes, Bernardete Pinheiro et al. · Value in Health · 2017 · 28 citations

Surgical Oncology, Health Economics, Medicine +7

Procedural Justice in Public Healthcare Resource Allocation

Aki Tsuchiya, L. Silva Miguel, Richard Edlin et al. · Applied Health Economics and Health Policy · 2005 · 23 citations

Public Policy, Law, Legal Process +4

Cost-Effectiveness of Pembrolizumab for The First-Line Treatment of Metastatic Non-Small Cell Lung Carcinoma in Portugal

BA Pinheiro, Joana Alarcão, L. Silva Miguel et al. · Value in Health · 2017 · 18 citations · Full text

Cost-Effectiveness of Rosuvastatin in the Prevention of Ischemic Heart Disease in Portugal

Carlos Gouveia Pinto, Manuel Carrageta, L. Silva Miguel · Value in Health · 2007 · 16 citations · Full text

Preventive Medicine, Health Economics, Health Policy +9